Literature DB >> 26931400

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary.

Harold J Burstein1, Christina Lacchetti2, Jennifer J Griggs1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26931400     DOI： 10.1200/JOP.2016.011239

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  13 in total

1.  Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.

Authors:  Shirley M Bluethmann; Caitlin C Murphy; Jasmin A Tiro; Michelle A Mollica; Sally W Vernon; Leona Kay Bartholomew
Journal:  Oncol Nurs Forum       Date:  2017-05-01       Impact factor: 2.172

2.  Utilization of genetic testing in breast cancer treatment after implementation of comprehensive multi-disciplinary care.

Authors:  Samfee Doe; Shariska Petersen; Monique Swain
Journal:  Breast J       Date:  2020-01-09       Impact factor: 2.431

Review 3.  Clinical practice guidelines in breast cancer.

Authors:  N Kumar Tyagi; S Dhesy-Thind
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

4.  The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications.

Authors:  Johanna Catherine Maclean; Michael T Halpern; Steven C Hill; Michael F Pesko
Journal:  Health Serv Res       Date:  2020-04-17       Impact factor: 3.402

5.  Accuracy of tumor registry versus pharmacy dispensings for breast cancer adjuvant endocrine therapy.

Authors:  Cameron B Haas; Erin J Aiello Bowles; Janie M Lee; Jennifer Specht; Diana S M Buist
Journal:  Cancer Causes Control       Date:  2022-07-07       Impact factor: 2.532

6.  Application value of modified radical mastectomy in female patients with breast cancer of different molecular types: a prognosis study.

Authors:  Bing Dong; Xiaoxing Yin; Han Xu; Kun Zhou; Longzhi Li; Baoxing Tian; Rongrong Cui
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

7.  Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.

Authors:  Yukinori Ozaki; Yuko Tanabe; Nobuko Tamura; Takuya Ogura; Chihiro Kondoh; Yuji Miura; Kenichi Yoshimura; Hidetaka Kawabata; Toshimi Takano
Journal:  Breast Cancer       Date:  2018-01-22       Impact factor: 4.239

8.  AFF3 upregulation mediates tamoxifen resistance in breast cancers.

Authors:  Yawei Shi; Yang Zhao; Yunjian Zhang; NiJiati AiErken; Nan Shao; Runyi Ye; Ying Lin; Shenming Wang
Journal:  J Exp Clin Cancer Res       Date:  2018-10-16

9.  Predictive factors affecting axillary lymph node involvement in patients with breast cancer in Duhok: Cross-sectional study.

Authors:  Ayad Ahmad Mohammed
Journal:  Ann Med Surg (Lond)       Date:  2019-07-10

10.  Study design and methods for the using exercise to relieve joint pain and improve AI adherence in older breast cancer survivors (REJOIN) trial.

Authors:  Shirley M Bluethmann; Cristina Truica; Heidi D Klepin; Nancy Olsen; Christopher Sciamanna; Vernon M Chinchilli; Kathryn H Schmitz
Journal:  J Geriatr Oncol       Date:  2021-05-26       Impact factor: 3.929
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.